Sunil Babu
Fort Wayne Medical Institute(US)Mayo Clinic in Arizona(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, Cancer Immunotherapy and Biomarkers, Complement system in diseases
Most-Cited Works
- → Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome(2013)1,539 cited
- → Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial(2022)641 cited
- → Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies(2015)412 cited
- → Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153(2020)228 cited
- → Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)(2018)223 cited
- → Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma(2021)216 cited
- → The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment(2020)208 cited
- → Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)(2019)185 cited
- → Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma(2021)156 cited
- → Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine(2022)141 cited